Novo Nordisk Reports; Amycretin Demonstrates Significant Glycemic Control And Weight Loss In Phase 2 Trial, Paving The Way For Phase 3 Development

Novo Nordisk has reported encouraging phase 2 clinical trial results for amycretin, a first-of-its-kind dual GLP-1 and amylin receptor agonist being developed for type 2 diabetes. The trial marks the therapy’s first evaluation in this patient population and reflects the company’s continued investment in next-generation metabolic treatments. Amycretin is being studied in both once-weekly subcutaneous and once-daily oral formulations.

The study enrolled 448 adults whose type 2 diabetes was insufficiently controlled on metformin with or without an SGLT2 inhibitor. Participants received a range of subcutaneous doses (0.4–40 mg weekly) or oral doses (6–50 mg daily) for up to 36 weeks. Both formulations produced meaningful and dose-dependent HbA1c reductions. Weekly subcutaneous dosing cut HbA1c by up to 1.8 percentage points, while daily oral dosing achieved reductions of up to 1.5 points—compared with minimal changes in the placebo groups.

“We are very encouraged by the phase 2 data with amycretin in people with type 2 diabetes - the first time amycretin has been evaluated in this population. The data further validate the potential best-in-class profile of amycretin” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk. “Amycretin is built on the complementary biology of GLP-1 and amylin, and we are looking forward to bringing amycretin into an extensive phase 3 development programme across multiple indications in 2026”.

Amycretin also resulted in significant weight loss. Participants receiving subcutaneous doses lost up to 14.5% of their baseline weight, and those on oral doses achieved reductions of up to 10.1%. These outcomes were markedly stronger than the 2–3% weight changes seen with placebo, and no plateau in weight loss was observed by week 36. Both versions of the drug were generally well tolerated, with mostly mild to moderate gastrointestinal side effects.

Following these promising findings, Novo Nordisk plans to begin phase 3 development of amycretin for adults with type 2 diabetes in 2026.